Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
暂无分享,去创建一个
A. De Luca | S. Lo Caputo | S. Di Giambenedetto | C. Torti | G. Carosi | P. Villani | E. Quiros-Roldan | A. Patroni | V. Micheli | M. Regazzi-Bonora
[1] V. Soriano,et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. , 2003, AIDS patient care and STDs.
[2] F. Gutiérrez,et al. Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir‐Containing Regimens , 2003, Journal of acquired immune deficiency syndromes.
[3] S. Khoo,et al. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. , 2003, AIDS.
[4] J. Collazos,et al. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. , 2003, AIDS.
[5] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[6] C. Tinelli,et al. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.
[7] R. Maserati,et al. Antiretrovirals: Simultaneous Determination of Five Protease Inhibitors and Three Nonnucleoside Transcriptase Inhibitors in Human Plasma by a Rapid High-Performance Liquid Chromatography–Mass Spectrometry Assay , 2001, Therapeutic drug monitoring.